ALHC vs. DXCM: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALHC and DXCM, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
DXCM stands out with 33.29 billion USD in market value—about 10.97× ALHC’s market cap of 3.03 billion USD.
With betas of 1.33 for ALHC and 1.44 for DXCM, both show similar volatility profiles relative to the overall market.
| Symbol | ALHC | DXCM |
|---|---|---|
| Company Name | Alignment Healthcare, Inc. | DexCom, Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Healthcare Plans | Medical - Devices |
| CEO | Mr. John E. Kao | Mr. Kevin Ronald Sayer |
| Price | 15.33 USD | 84.89 USD |
| Market Cap | 3.03 billion USD | 33.29 billion USD |
| Beta | 1.33 | 1.44 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | March 26, 2021 | April 14, 2005 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALHC and DXCM over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ALHC and DXCM based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ALHC posts a negative P/E of -32.75, reflecting last year’s net loss, while DXCM at 62.03 signals healthy earnings.
- ALHC posts a negative forward PEG of -1.11, hinting at anticipated earnings decline, whereas DXCM at 2.83 has projections for stable or growing earnings.
| Symbol | ALHC | DXCM |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -32.75 | 62.03 |
| Forward PEG Ratio (TTM) | -1.11 | 2.83 |
| Price-to-Sales Ratio (P/S, TTM) | 1.01 | 8.02 |
| Price-to-Book Ratio (P/B, TTM) | 27.45 | 14.65 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 159.00 | 57.87 |
| EV-to-EBITDA (TTM) | -64.47 | 39.29 |
| EV-to-Sales (TTM) | 0.86 | 8.43 |
| EV-to-Free Cash Flow (TTM) | 136.01 | 60.79 |
Dividend Comparison
Neither ALHC nor DXCM currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ALHC | DXCM |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ALHC and DXCM, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- With negative EBIT (-2.98), ALHC cannot cover its interest payments. DXCM, with an interest coverage of 43.93, meets its interest obligations.
| Symbol | ALHC | DXCM |
|---|---|---|
| Current Ratio (TTM) | 1.69 | 1.50 |
| Quick Ratio (TTM) | 1.69 | 1.32 |
| Debt-to-Equity Ratio (TTM) | 0.07 | 1.14 |
| Debt-to-Assets Ratio (TTM) | 0.01 | 0.38 |
| Interest Coverage Ratio (TTM) | -2.98 | 43.93 |